PL2037922T3 - Inhibitory hydroksylazy prolilowej - Google Patents

Inhibitory hydroksylazy prolilowej

Info

Publication number
PL2037922T3
PL2037922T3 PL07798915T PL07798915T PL2037922T3 PL 2037922 T3 PL2037922 T3 PL 2037922T3 PL 07798915 T PL07798915 T PL 07798915T PL 07798915 T PL07798915 T PL 07798915T PL 2037922 T3 PL2037922 T3 PL 2037922T3
Authority
PL
Poland
Prior art keywords
prolyl hydroxylase
hydroxylase inhibitors
inhibitors
prolyl
hydroxylase
Prior art date
Application number
PL07798915T
Other languages
English (en)
Inventor
Kevin J Duffy
Duke M Fitch
Jian Jin
Ronggang Liu
Antony N Shaw
Kenneth Wiggall
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38834409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2037922(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of PL2037922T3 publication Critical patent/PL2037922T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
PL07798915T 2006-06-23 2007-06-22 Inhibitory hydroksylazy prolilowej PL2037922T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80560206P 2006-06-23 2006-06-23
EP07798915.0A EP2037922B9 (en) 2006-06-23 2007-06-22 Prolyl hydroxylase inhibitors
PCT/US2007/071854 WO2007150011A2 (en) 2006-06-23 2007-06-22 Prolyl hydroxylase inhibitors

Publications (1)

Publication Number Publication Date
PL2037922T3 true PL2037922T3 (pl) 2014-06-30

Family

ID=38834409

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07798915T PL2037922T3 (pl) 2006-06-23 2007-06-22 Inhibitory hydroksylazy prolilowej

Country Status (31)

Country Link
US (10) US8324208B2 (pl)
EP (1) EP2037922B9 (pl)
JP (1) JP5203361B2 (pl)
KR (1) KR101411816B1 (pl)
CN (1) CN101505752B (pl)
AR (1) AR061570A1 (pl)
AU (1) AU2007260837B2 (pl)
BR (1) BRPI0713446B8 (pl)
CA (1) CA2655491C (pl)
CR (1) CR10534A (pl)
DK (1) DK2037922T3 (pl)
EA (1) EA018220B1 (pl)
ES (1) ES2453100T3 (pl)
HK (1) HK1130671A1 (pl)
HR (1) HRP20140306T1 (pl)
IL (1) IL196070A (pl)
JO (1) JO2934B1 (pl)
MA (1) MA30526B1 (pl)
MX (1) MX2009000165A (pl)
MY (1) MY149861A (pl)
NO (1) NO342019B1 (pl)
NZ (1) NZ573698A (pl)
PE (1) PE20080209A1 (pl)
PL (1) PL2037922T3 (pl)
PT (1) PT2037922E (pl)
SG (1) SG174775A1 (pl)
SI (1) SI2037922T1 (pl)
TW (1) TWI394747B (pl)
UA (1) UA100225C2 (pl)
WO (1) WO2007150011A2 (pl)
ZA (1) ZA200810602B (pl)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090299063A1 (en) * 2005-03-29 2009-12-03 Paul Shapiro Inhibitors for Extracellular Signal-Regulated Kinase Docking Domains and Uses Therefor
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
PE20080209A1 (es) * 2006-06-23 2008-05-15 Smithkline Beecham Corp Derivados de glicina como inhibidores de prolil hidroxilasa
DE602007009992D1 (de) 2006-06-26 2010-12-02 Warner Chilcott Co Llc Prolylhydroxylase-hemmer und verfahren zu ihrer anwendung
GB0622472D0 (en) * 2006-11-10 2006-12-20 Addex Pharmaceuticals Sa Novel heterocyclic derivatives
ES2393326T3 (es) 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
EP2111399A2 (en) 2006-12-18 2009-10-28 Amgen Inc. Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
US8048894B2 (en) 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
CA2683738C (en) 2007-04-18 2012-03-20 Amgen Inc. Indanone derivatives that inhibit prolyl hydroxylase
US8097620B2 (en) 2007-05-04 2012-01-17 Amgen Inc. Diazaquinolones that inhibit prolyl hydroxylase activity
CA2685216C (en) 2007-05-04 2014-07-08 Amgen Inc. Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
MX2010002905A (es) * 2007-09-17 2010-07-05 Abbott Lab Derivados de uracilo o timina para tratar la hepatitis c.
US8952160B2 (en) 2008-01-11 2015-02-10 Fibrogen, Inc. Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
CA2718528C (en) 2008-03-18 2016-10-25 Merck Sharp & Dohme Corp. Substituted 4-hydroxypyrimidine-5-carboxamides
WO2009134750A1 (en) 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
GB0809262D0 (en) 2008-05-21 2008-06-25 Isis Innovation Assay
WO2009158315A1 (en) * 2008-06-25 2009-12-30 Smithkline Beecham Corporation Prolyl hydroxylase inhibitors
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
EP2326179A4 (en) * 2008-08-25 2011-08-17 Smithkline Beecham Corp PROLYLHYDROXYLASEHEMMER
NZ592741A (en) 2008-11-14 2013-03-28 Fibrogen Inc Thiochromene derivatives as hif hydroxylase inhibitors
EP2396316B1 (en) 2009-02-10 2015-07-01 Janssen Pharmaceutica, N.V. Quinazolinones as prolyl hydroxylase inhibitors
BRPI1013561A8 (pt) 2009-03-26 2015-09-22 Mapi Pharma Ltd processo para a preparação de alogliptina
EP3144299A1 (en) * 2009-05-05 2017-03-22 Cambria Pharmaceuticals, Inc. Pyrimidine-2,4,6-triones for use in the treatment of amyotrophic lateral sclerosis
ME01858B (me) * 2009-07-17 2014-12-20 Japan Tobacco Inc Jedinjenje triazolopiridina i njegovo dejstvo kao inhibitora prolil hidroksilaze i induktora proizvodnje eritropoetina
TWI500623B (zh) * 2009-10-13 2015-09-21 Torrent Pharmaceuticals Ltd 新穎稠合噻唑及噁唑嘧啶酮
PT2492266E (pt) 2009-10-21 2015-11-18 Daiichi Sankyo Co Ltd Derivado de 5-hidroxipirimidino-4-carboxamida
ES2533128T3 (es) 2009-11-06 2015-04-07 Aerpio Therapeutics Inc. Inhibidores de la prolilhidroxilasa
WO2012021830A1 (en) 2010-08-13 2012-02-16 Janssen Pharmaceutica Nv 4 - aminoquinazolin- 2 - yl - 1 - pyrrazole - 4 - carboxylic acid compounds as prolyl hydroxylase inhibitors
CN103608346B (zh) 2011-02-02 2016-06-15 菲布罗根有限公司 作为缺氧诱导因子(hif)羟化酶抑制剂的萘啶衍生物
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
NO2686520T3 (pl) 2011-06-06 2018-03-17
EP2717870B1 (en) 2011-06-06 2017-09-27 Akebia Therapeutics Inc. Composition for stabilizing hypoxia inducible factor-2 alpha useful for treating cancer
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
EP2758059B1 (en) 2011-09-23 2018-10-24 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2013043621A1 (en) 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2013040790A1 (en) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
WO2013040789A1 (en) * 2011-09-23 2013-03-28 Merck Sharp & Dohme Corp. Substituted pyrimidines
CN102432549B (zh) * 2011-09-28 2014-09-03 南通市华峰化工有限责任公司 一种抑制血管生成、肿瘤发生和增殖疾病的药物中间体1,3-二环己基巴比妥酸的制备方法
ES2689481T3 (es) 2011-10-25 2018-11-14 Janssen Pharmaceutica Nv Formulaciones de sal de meglumina de ácido 1-(5,6-dicloro-1h-benzo[d]imidazol-2-il)-1h-pirazol-4-carboxílico
US20140309256A1 (en) * 2011-11-09 2014-10-16 Fibrogen, Inc. Therapeutic Method
UA112897C2 (uk) 2012-05-09 2016-11-10 Байєр Фарма Акцієнгезелльшафт Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань
MY195209A (en) 2012-07-30 2023-01-11 Taisho Pharmaceutical Co Ltd Partially Saturated Nitrogen-Containing Heterocyclic Compound
CN103146720B (zh) * 2013-03-01 2014-12-03 河北博伦特药业有限公司 一种具有高转化率的反式-4-羟基-l-脯氨酸羟化酶改造基因及其应用
PE20160194A1 (es) 2013-06-13 2016-04-20 Akebia Therapeutics Inc Composiciones y metodos para tratar anemia
CA2929763A1 (en) 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituted uracils as chymase inhibitors
WO2015067630A1 (de) * 2013-11-08 2015-05-14 Bayer Pharma Aktiengesellschaft Substituierte uracile und ihre verwendung
CR20160222U (es) 2013-11-15 2016-08-26 Akebia Therapeutics Inc Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
JP5975122B2 (ja) * 2014-01-29 2016-08-23 大正製薬株式会社 ［（４−ヒドロキシ−２−オキソ−１，２，５，６−テトラヒドロ−３−ピリジニル）カルボニル］グリシン化合物の結晶形及びそれらの製造方法
US9388135B2 (en) 2014-02-19 2016-07-12 Aerpio Therapeutics, Inc. Process for preparing N-benzyl-3-hydroxy-4-substituted-pyridin-2-(1H)-ones
CN104151254A (zh) * 2014-07-25 2014-11-19 南通市华峰化工有限责任公司 一种制备1，3-双环己基巴比妥酸的方法
ES2898476T3 (es) 2014-09-02 2022-03-07 Sunshine Lake Pharma Co Ltd Compuesto de quinolona y uso del mismo
WO2016054806A1 (en) * 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. Substittued pyridine inhibitors of hif prolyl hydroxylase
WO2016054805A1 (en) * 2014-10-10 2016-04-14 Merck Sharp & Dohme Corp. Substituted pyrimidines as inhibitors of hif prolyl hydroxylase
JP2018039733A (ja) * 2014-12-22 2018-03-15 株式会社富士薬品 新規複素環誘導体
TW201632504A (zh) 2015-01-23 2016-09-16 阿克比治療有限公司 ２－（５－（３－氟苯基）－３－羥吡啶醯胺基）乙酸之固體形式、其組合物及其用途
CN106146395B (zh) 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
EA036920B1 (ru) 2015-04-01 2021-01-15 Экебиа Терапьютикс, Инк. Композиции и способы для лечения анемии
US10401548B2 (en) * 2015-09-24 2019-09-03 Intel Corporation Integrated antenna with display uniformity
KR102686073B1 (ko) 2015-10-14 2024-07-17 엑스-써마 인코포레이티드 얼음 결정 형성을 감소시키기 위한 조성물 및 방법
JP6325139B2 (ja) * 2016-03-02 2018-05-16 ネルファルマ・エッセ・エッルレ・エッレ カルムスチンの安全で効率的な製造方法
JP7142406B2 (ja) 2017-05-09 2022-09-27 カインド ファーマシューティカル インドリジン誘導体及びその医学的応用
CN111518038B (zh) * 2017-05-26 2022-04-05 深圳市塔吉瑞生物医药有限公司 一种取代的嘧啶三酮化合物及包含该化合物的组合物及其用途
WO2019052133A1 (zh) 2017-09-15 2019-03-21 苏州科睿思制药有限公司 Gsk1278863的晶型及其制备方法和制药用途
TWI822776B (zh) 2018-05-09 2023-11-21 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
CN109134356A (zh) * 2018-06-18 2019-01-04 苏州盖德精细材料有限公司 一种中间体2-氨基吡啶-4-甲醇的制备方法
EP3880663A1 (en) 2018-11-15 2021-09-22 Teva Pharmaceuticals International GmbH Solid state forms of daprodustat and process for preparation thereof
WO2021000933A1 (zh) * 2019-07-03 2021-01-07 南京明德新药研发有限公司 作为糜酶抑制剂的嘧啶酮类化合物及其应用
WO2021031102A1 (zh) * 2019-08-20 2021-02-25 深圳仁泰医药科技有限公司 Daprodustat的晶型及其制备方法和用途
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
BR112022024533A2 (pt) 2020-06-19 2022-12-27 Glaxosmithkline Ip No 2 Ltd Formulação compreendendo daprodustat
WO2022135534A1 (zh) * 2020-12-25 2022-06-30 广东东阳光药业有限公司 取代的含氮双环化合物及其用途
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
WO2022179967A1 (en) 2021-02-23 2022-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Vadadustat for treating covid-19 in a hospitalized subject
EP4347022A1 (en) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pediatric formulations of ferric citrate
EP4355734A1 (en) 2021-06-18 2024-04-24 GlaxoSmithKline Intellectual Property (No. 2) Limited Novel manufacturing method of daprodustat and precursors thereof
IT202200008693A1 (it) 2022-04-29 2023-10-29 Dipharma Francis Srl Metodo per la preparazione e la purificazione di un agente per il trattamento dell'anemia
IT202100020609A1 (it) 2021-07-30 2023-01-30 Dipharma Francis Srl Metodo di preparazione di agente adatto per il trattamento dell'anemia
WO2023006986A1 (en) 2021-07-30 2023-02-02 Dipharma Francis S.R.L. Method for preparing and purifying an agent suitable for treating anemia
IT202100020591A1 (it) 2021-07-30 2023-01-30 Dipharma Francis Srl Preparazione di un intermedio di un agente per il trattamento dell'anemia
WO2024022998A1 (en) 2022-07-26 2024-02-01 Inke, S.A. Process for preparing daprodustat and cocrystals thereof
GB202211231D0 (en) 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation
GB202301059D0 (en) 2023-01-25 2023-03-08 Univ Oxford Innovation Ltd PHD inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0424064T3 (da) 1989-10-16 1995-06-26 Chiroscience Ltd Chirale azabicycloheptanoner og fremgangsmåde til fremstilling deraf
ATE149485T1 (de) * 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
AU5316900A (en) * 1999-06-03 2000-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk)
US6878743B2 (en) * 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
CA2916093C (en) * 2001-12-06 2020-11-03 Fibrogen, Inc. Use of hif prolyl hydroxylase inhibitors for treating neurological disorders
US7180893B1 (en) 2002-03-22 2007-02-20 Juniper Networks, Inc. Parallel layer 2 and layer 3 processing components in a network router
CA2497656A1 (en) * 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
CN102977016B (zh) 2003-06-06 2015-01-14 菲布罗根有限公司 含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
JP2007505121A (ja) * 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
CN102127053A (zh) * 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
JP2007277096A (ja) 2004-07-15 2007-10-25 Astellas Pharma Inc フェネチルニコチンアミド誘導体含有医薬
US7718624B2 (en) * 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
CN101394843A (zh) * 2005-06-06 2009-03-25 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
EP1947943A4 (en) * 2005-10-21 2009-11-25 Univ Alabama SMALL MOLECULAR INHIBITORS OF HIV-1 CAPSIDE FORMATION
US7713986B2 (en) * 2006-06-15 2010-05-11 Fibrogen, Inc. Compounds and methods for treatment of chemotherapy-induced anemia
US20070293575A1 (en) * 2006-06-15 2007-12-20 Fibrogen, Inc. Compounds and methods for treatment of cancer-related anemia
TW200817006A (en) * 2006-06-23 2008-04-16 Smithkline Beecham Corp IL-8 receptor antagonist
PE20080209A1 (es) * 2006-06-23 2008-05-15 Smithkline Beecham Corp Derivados de glicina como inhibidores de prolil hidroxilasa
WO2008040002A2 (en) 2006-09-28 2008-04-03 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for hif modulating compounds
WO2008073292A2 (en) * 2006-12-08 2008-06-19 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Method for protecting renal tubular epithelial cells from radiocontrast nephro parhy (rcn)
CL2008000065A1 (es) 2007-01-12 2008-09-22 Smithkline Beecham Corp Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
WO2019052133A1 (zh) 2017-09-15 2019-03-21 苏州科睿思制药有限公司 Gsk1278863的晶型及其制备方法和制药用途
EP3880663A1 (en) 2018-11-15 2021-09-22 Teva Pharmaceuticals International GmbH Solid state forms of daprodustat and process for preparation thereof

Also Published As

Publication number Publication date
KR101411816B1 (ko) 2014-06-24
US11643397B2 (en) 2023-05-09
NO20090202L (no) 2009-03-23
BRPI0713446B8 (pt) 2021-05-25
EP2037922A2 (en) 2009-03-25
EP2037922B9 (en) 2017-08-23
IL196070A0 (en) 2009-09-01
US20180305323A1 (en) 2018-10-25
US10336711B2 (en) 2019-07-02
US20160297772A1 (en) 2016-10-13
HK1130671A1 (en) 2010-01-08
CR10534A (es) 2009-03-20
PE20080209A1 (es) 2008-05-15
CA2655491A1 (en) 2007-12-27
EP2037922A4 (en) 2012-08-22
DK2037922T3 (en) 2014-03-24
UA100225C2 (uk) 2012-12-10
US8324208B2 (en) 2012-12-04
WO2007150011A8 (en) 2008-07-10
SI2037922T1 (sl) 2014-04-30
BRPI0713446B1 (pt) 2019-10-29
EA200970050A1 (ru) 2009-06-30
US20100113444A1 (en) 2010-05-06
US10035779B2 (en) 2018-07-31
HRP20140306T1 (hr) 2014-05-09
US20140024666A1 (en) 2014-01-23
US20230227414A1 (en) 2023-07-20
NO342019B1 (no) 2018-03-12
US20210347740A1 (en) 2021-11-11
US20130072487A1 (en) 2013-03-21
WO2007150011A3 (en) 2008-03-27
AU2007260837A1 (en) 2007-12-27
ZA200810602B (en) 2010-10-27
JP5203361B2 (ja) 2013-06-05
WO2007150011A2 (en) 2007-12-27
BRPI0713446A2 (pt) 2012-03-06
IL196070A (en) 2015-05-31
MY149861A (en) 2013-10-31
KR20090030321A (ko) 2009-03-24
EP2037922B1 (en) 2014-01-22
CA2655491C (en) 2016-09-06
ES2453100T3 (es) 2014-04-04
US20150315157A1 (en) 2015-11-05
TW200815364A (en) 2008-04-01
JO2934B1 (en) 2015-09-15
AU2007260837B2 (en) 2013-07-04
US20140336383A1 (en) 2014-11-13
EA018220B1 (ru) 2013-06-28
SG174775A1 (en) 2011-10-28
MA30526B1 (fr) 2009-06-01
NZ573698A (en) 2012-02-24
PT2037922E (pt) 2014-04-14
JP2009541351A (ja) 2009-11-26
CN101505752B (zh) 2012-12-05
CN101505752A (zh) 2009-08-12
US8557834B2 (en) 2013-10-15
MX2009000165A (es) 2009-01-23
US20200157055A1 (en) 2020-05-21
AR061570A1 (es) 2008-09-03
TWI394747B (zh) 2013-05-01
US8815884B2 (en) 2014-08-26

Similar Documents

Publication Publication Date Title
IL196070A0 (en) Prolyl hydroxylase inhibitors
EP2227770A4 (en) PROLYLHYDROXYLASEINHIBITOREN
EP2240178A4 (en) PROLYLHYDROXYLASEHEMMER
EP2224926A4 (en) INHIBITORS OF PROLYL HYDROXYLASES
EP2326178A4 (en) INHIBITORS OF PROLYL-HYDROXYLASE
HRP20141038T1 (en) Benzoimidazoles as prolyl hydroxylase inhibitors
HK1190334A1 (en) Prolyl hydroxylase inhibitors
ZA200807457B (en) Pyrrolidine derivatives as ERK inhibitors
GB0619753D0 (en) Enzyme inhibitors
EP1926485A4 (en) HIF-INHIBITORS
EP2273879A4 (en) PROLYLHYDROXYLASEHEMMER
EP2326179A4 (en) PROLYLHYDROXYLASEHEMMER
IL194339A0 (en) Enzyme inhibitors
EP2015745A4 (en) MACROCYCLIC KINASE INHIBITORS
ZA200810025B (en) Cox-2 inhibitor
EP2306828A4 (en) INHIBITORS OF PROLYL HYDROXYLASES
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL193981A0 (en) Novel heterocyclic nf-kb inhibitors
GB0608844D0 (en) Enzyme inhibitors
GB0617161D0 (en) Enzyme inhibitors
GB0516967D0 (en) Inhibitors
SI2496236T1 (sl) Prolilhidroksilazni inhibitorji
GB0612544D0 (en) Enzyme inhibitors
GB0620884D0 (en) Enzyme inhibitors
GB0624958D0 (en) Enzyme inhibitors